SCHEMBL12428148

SCHEMBL12428148

O=C(c1cc2c(ccc3ccccc32)[nH]1)n1ccnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
KDM4E B2RXH2 2/20 0.58
HSD17B10 Q99714 2/20 0.58
LMNA P02545 1/20 0.58
TBXAS1 P24557 2/20 0.39
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36
TUBB3 Q13509 1/20 0.36
TUBB2A Q13885 1/20 0.36
TUBB8 Q3ZCM7 1/20 0.36
TUBA3E Q6PEY2 1/20 0.36
TUBA1A Q71U36 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12427429 0.83 ALDH1A1 (0.57) ALDH1A1KDM4EHSD17B10LMNATBXAS1
SCHEMBL6396188 0.82 FLT3 (0.54) ALDH1A1KDM4EHSD17B10HPGDHRH4
SCHEMBL9288910 0.81 CYP17A1 (0.44) ALDH1A1KDM4EHSD17B10LMNATBXAS1
SCHEMBL25667602 0.75 HRH4 (0.59) KDM4ELMNAMEN1KMT2ATUBB4A
SCHEMBL30009269 0.75 ALDH1A1 (0.62) ALDH1A1KDM4EHSD17B10LMNAMEN1
SCHEMBL2302776 0.75 ALDH1A1 (0.62) ALDH1A1KDM4EHSD17B10LMNAMEN1
SCHEMBL3601642 0.74 HSD17B10 (1.00) ALDH1A1KDM4EHSD17B10LMNAMEN1
SCHEMBL10118094 0.74 ALDH1A1 (0.54) ALDH1A1KDM4ELMNATBXAS1KMT2A
SCHEMBL4459257 0.73 HSD17B10 (0.73) ALDH1A1KDM4EHSD17B10LMNAMEN1
SCHEMBL7495494 0.72 GABRA1 (0.60) ALDH1A1KDM4EHSD17B10LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9403769-B2 Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics ADVANCED CANCER THERAPEUTICS, LLC (US) 2016-08-02 US disclosed
US-9403769-B2 Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics ADVANCED CANCER THERAPEUTICS, LLC (US) 2016-08-02 US disclosed
US-20130059879-A1 Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2013-03-07 US disclosed
US-20130059879-A1 Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2013-03-07 US disclosed
WO-2011103557-A1 SMALL MOLECULE INHIBITORS OF PFKFB3 AND GLYCOLYTIC FLUX AND THEIR METHODS OF USE AS ANTI-CANCER THERAPEUTICS ADVANCED CANCER THERAPEUTICS, LLC (US) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059879-A1 Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics PFKFB3, PFKFB1, PFKFB2 ALDH1A1 1970/4885KDM4E 1704/4885HSD17B10 1711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.